Acute kidney injury (AKI) is the new consensus term for acute renal failure. The term describes a continuum of kidney injury, a common condition in the critically ill and after major surgery, which is associated with increased mortality. The incidence of AKI in intensive care unit patients in Australia is >30% and sepsis is a major contributory factor. However, there is limited knowledge about its incidence after major surgery, except for cardiac surgery. The creation of staged AKI classification systems (RIFLE [Risk, Injury, Failure, Loss, Endstage], Acute Kidney Injury Network and the new Kidney Disease: Improving Global Outcomes criteria) has accelerated progress in critical care nephrology research by showing that even small changes in serum creatinine are associated with increased risk of death and that this risk increases progressively with severity of AKI. Recent thought and research has cast doubt over previously accepted pathophysiological views of AKI. Moreover, terms such as 'prerenal azotaemia' and 'acute tubular necrosis' are now being challenged as lacking validity, having little supportive evidence and carrying limited clinical utility. In this review, we explore the limitations of animal and human models of AKI and the implications of recent research on our current understanding of the pathophysiology of AKI. In addition, we describe conventional and novel diagnostic methods and therapies, and explore the clinical implications of the effect of fluid administration and perioperative management. Finally, we identify priorities for clinical investigations and future directions in AKI research.
Acute kidney injury (AKI) is a consensus term now used to describe the continuum of injury previously called acute renal failure 1 . It is a common complication in the critically ill and is one of the most serious complications of critical illness and after cardiac surgery, being independently associated with an increased risk of death 2 and with prolonged intensive care unit (ICU) and hospital length-ofstay 3, 4 , which implies an increase in resource use and cost ( Figure 1 ). As the severity of AKI increases, so does the risk of adverse outcomes 2, 4, 5 . AKI refers to a 'syndrome' involving a rapid reduction in renal excretory capacity with accumulation, among others, of nitrogen waste products such as creatinine and urea (called azotaemia). The concentration of potassium, phosphate and metabolic acids also typically increases. The term AKI implies a continuum of injury; studies confirm that even small increases in serum creatinine are associated with increased mortality and risk rises progressively as serum creatinine increases 2 .
The International Acute Dialysis Quality Initiative consensus conferences led to the development of the RIFLE (Risk, Injury, Failure, Loss, Endstage) classification system to define AKI 1 ( Figure  2 ). This classification system incorporates change in renal function from baseline, is easy to use and is clinically applicable across centres. The RIFLE system provides a framework to aid stratification and randomisation of AKI patients into clinical trials. It has facilitated comparison of studies on a large scale and has enhanced progress in scientific investigation of critical care nephrology. The recently developed Acute Kidney Injury Network (AKIN) criteria for AKI are based on the RIFLE system with minor modifications: more 'permissive' criteria for AKIN stage 1 (equivalent to RIFLE 'risk' category) and the (Figure 2 ). The more recently developed Kidney Disease: Improving Global Outcomes (KDIGO) classification system 7 combines the RIFLE and the AKIN criteria with its own minor modifications ( Figure 3 ). Although the AKIN criteria were designed to improve sensitivity in diagnosing AKI, this has not been demonstrated and comparative studies show that AKIN does not improve the ability to predict outcomes compared to RIFLE [8] [9] [10] [11] . The RIFLE criteria have been more extensively used and validated to classify renal function in clinical studies to date, involving over 550,000 subjects worldwide 12 .
Furthermore, a recent multicentre study of thousands of intensive care unit (ICU) patients found RIFLE to be a more robust measure, with a higher detection rate of AKI in the first 48 hours after ICU admission 9 . In this study, the AKIN criteria were more likely to misclassify patients as non-AKI compared with the RIFLE criteria. The novel KDIGO criteria have been formulated very recently and require validation.
INCIDENCE
The incidence of AKI (RIFLE R, I or F) in critically ill patients in large Australian and European studies is about 36% 13, 14 , and sepsis is one of the major contributors to its development 15 . Data from 57 Australian and New Zealand ICUs (n=120, 123 patients) found that 27.8% of all patients had a sepsisrelated diagnosis, 42% of patients with sepsis had AKI and of all patients with AKI, 32.4% had sepsis 16 . In more severe sepsis the occurrence of AKI is even more common 17 .
In developed countries, after sepsis, cardiac surgery is the second most common trigger of AKI 4 . Trauma is also an important cause of AKI. In Australia and New Zealand, the crude incidence of early AKI (within 24 hours of admission) in critically ill trauma patients (n=9449) was 18.1% and around 10% in patients with traumatic brain injury 18, 19 .
The incidence of AKI in intensive care and cardiac surgical settings has increased 20, 21 and, despite progress in many aspects of medicine, mortality rates in patients with AKI have improved only marginally 20 suggests an increase in the burden of illness associated with AKI. Moreover, the marginal improvement in mortality rates, despite an increased incidence of AKI, suggests greater cost and resource use in the treatment of these patients 20 .
AETIOLOGY
The causes or triggers of AKI have been traditionally divided into prerenal, postrenal and intrinsic causes to simplify this continuum of injury, which results from multiple mechanisms. Certain syndromes also lead to the development of AKI, as do certain drugs.
Prerenal AKI
This term refers to AKI occurring in response to extrarenal diseases such as septic shock, cardiogenic shock, hypovolaemia and bleeding. Most severe AKIs stem from a prerenal cause 22 .
Renal AKI
Renal, 'intrinsic' or 'parenchymal' AKI occurs as a result of pathological processes often of an inflammatory nature that primarily affect the renal tissue itself, (e.g. glomerulonephritis, acute interstitial nephritis, pyelonephritis and vasculitis).
The term 'Renal AKI' also traditionally encompasses ischaemia-induced structural injury to the kidneys (often referred to as acute tubular necrosis [ATN]) typically resulting from severe 'prerenal AKI'. Histological changes in ATN are believed to involve localised necrosis of the renal tubule epithelium, with focal rupture or loss of basement membrane. Necrotic cells (casts) are shed into the tubule lumen, obliterating it and causing AKI. If the tubular basement membrane is intact, regeneration is possible. In this setting, the boundaries of functional prerenal injury and structural changes become blurred, as prolonged renal ischaemia leads to increased renal damage and 'prerenal AKI' becomes 'renal AKI' 23 .
Postrenal AKI
Post-renal AKI occurs as a result of obstruction of urinary outflow (e.g. renal calculi, papillary necrosis and surgical ureteric injury). Elevated intraabdominal pressure may cause AKI.
Problems with traditional aetiological concepts
ATN and prerenal azotaemia are two key concepts related to AKI. Both are considered to stem from prerenal causes. It is thought that prerenal azotaemia is not associated with histopathological changes and patients with prerenal azotaemia are considered likely to respond to fluid therapy, whereas ATN involves structural injury and changes. If it is prolonged, prerenal azotaemia (no histological changes) is taken to lead to ATN, a generally unconfirmed histological diagnosis 24 . There are inconsistencies and conceptual flaws here 24, 25 . In the absence of confirmation of histological changes (renal biopsies are rarely performed) these terms that assume the presence or absence of structural injury cannot be reliably assigned. Moreover, the use of separate diagnoses to identify conditions that may refer to different stages of a progressive disease does not reflect the complicated continuum of injury that AKI represents. Indeed, the terms ATN and prerenal azotaemia may have limited clinical utility.
SPECIFIC AKI SyNDRoMES

Hepatorenal syndrome
The hepatorenal syndrome describes a type of AKI occurring with severe liver disease. It involves progressive oliguria with very low urine sodium levels (<10 mmol/l). However, other causes of AKI are in fact more common in patients with severe liver disease (e.g. sepsis, cardiomyopathy or hypovolaemia due to diuresis/paracentesis). AKI in this setting mirrors sepsis in that it seems to occur without renal histopathological changes. However, unlike animal models of sepsis, renal vasoconstriction is intense along with significant renin-angiotensinaldosterone system (RAAS) activation, suggesting neurohormonal involvement. Hypotension due to splanchnic vasodilation seems to be involved in activating vasoconstriction and RAAS 26 , which bolsters the systemic circulation, but the renal circulation might suffer. In postoperative systemic inflammatory response syndrome a similar situation may occur, with elevated noradrenaline, renin and angiotensin II levels leading to AKI. However, this has not been investigated. Recently, in patients with hepatorenal syndrome, terlipressin, a long-acting vasopressin derivative is being used to improve glomerular filtration rate (GFR) with effect 27, 28 . Its mechanism of action is thought to be through splanchnic vasoconstriction and redistribution of blood flow away from a dilated splanchnic bed which may increase central circulatory volume and renal blood flow.
Cardiorenal syndrome
The co-existence of heart failure and kidney disease in many patients has emerged as a focus of epidemiological and therapeutic interest. Cardiorenal syndrome involves deleterious interaction between these two organs. Whether the heart or kidney fails primarily, this precipitates the failure of the other organ. Neurohormonal activity, anaemia, oxidative stress and renal sympathetic activity are potential contributors to this complex syndrome. The occurrence of AKI with chronic kidney disease in such patients may be triggered by an acute decompensation of their heart failure. Indeed, initial work in this area hints that a congestive state, more than decreased forward output or pressure, may contribute more to the development of AKI 29 .
Rhabdomyolysis-induced AKI
Rhabdomyolysis is typically seen following major trauma, drug overdose, vascular embolism and in response to agents that induce muscular injury. It can also develop as a complication of cardiac surgery. All causes have a common pathway involving prerenal, renal and postrenal factors. Calcium release from the sarcolemma and cytosolic calcium overload lead to muscle cell damage and the release of myocyte constituents into the circulation. one of the key compounds released is myoglobin, a haem-containing protein that plays a major role in the development of AKI 30 . Indeed, creatine kinase and free myoglobin levels are used to diagnose rhabdomyolysis 31 . Randomised, controlled trials have not been performed in this area, so management is based on data from small studies and includes early, aggressive fluid resuscitation, elimination of causative agents, compartment syndrome correction, urine alkalinisation to pH >6.5 and diuresis (>300 ml/ hour).
Drug-induced AKI
Drugs appear to contribute to AKI, particularly in ICU patients, in approximately 20% of cases 32 . Drugs that can rapidly induce prerenal AKI include non-steroidal anti-inflammatory drugs, angiotensinconverting-enzyme inhibitors and cyclosporin. Nonsteroidal anti-inflammatory drugs, which inhibit prostaglandin synthesis, reduce GFR by blocking the effect of renal vasodilatory prostaglandins in hypoperfused states 33 . Angiotensin-convertingenzyme inhibitors may induce prerenal AKI by reducing the production of angiotensin II, which maintains glomerular capillary hydrostatic pressure by constricting the glomerular efferent arterioles 34 . Cyclosporin A and other immunosuppressive drugs, such as tacrolimus and sirolimus, also cause vasoconstriction of the afferent arterioles which reduces renal perfusion, thus decreasing GFR and inducing AKI 35 .
other nephrotoxic drugs that can cause or contribute to the development of AKI include aminoglycosides, amphotericin B, sulphonamides, acyclovir, methotrexate, angiotensin receptor blockers and radiocontrast agents. Importantly, in drug-induced AKI, the causative agent can often be identified and removed or replaced by a less nephrotoxic agent.
Contrast-induced AKI
Contrast-induced AKI (CI-AKI) is a common iatrogenic cause of AKI after angiographic procedures and angioplasty and is associated with adverse outcomes. Proposed mechanisms of the pathogenesis of CI-AKI include two main theories: renal vasoconstriction resulting in medullary hypoxaemia (mediated by changes in nitric oxide, endothelin or adenosine) and the direct cytotoxic effects of the contrast 36, 37 (Figure 4 ). Evidence shows that CI-AKI can be reduced by the use of iso-osmolar agents 38 , and the incidence of postoperative AKI in patients undergoing elective cardiac surgery may be reduced by delaying surgery beyond 24 hours after exposure to contrast agents and by minimising their use 39 . The utility of fenoldopam to reduce renal injury in CI-AKI has been refuted in two randomised controlled trials 40, 41 . Volume expansion is recommended to count-eract the effect of radiocontrast in the KDIGO clinical practice guidelines ( Figure 4 ). While there is a potent-ial (but inconsistent) benefit of bicarbonate solutions, the KDIGO guidelines recommend the use of either isotonic sodium chloride or sodium bicarbonate intravenous solutions 7 . There is no clear evidence regarding optimal rate and duration of infusion, however, most studies suggest starting fluids ≥1 hour before and continuing for three to six hours after contrast administration 7 . The evidence for an overall benefit of N-acetylcysteine (NAC) is not consistent 42 , but oral NAC has low-risk for adverse events and a low cost, and therefore its use prior to radiocontrast procedures is acceptable 7 . A large factorial design study called Prevention of serious adverse events following angiography (NCT01467466, n=8680, see Further Reading) is soon to start in the USA, Australia and New Zealand. It will compare N-acetylcysteine versus placebo and sodium bicarbonate versus saline, looking at differences in mortality, dialysis or persistent decline in kidney function at 90 days. This trial could provide definitive answers regarding the use of NAC and bicarbonate for CI-AKI prevention.
RISK FACToRS FoR AKI
Risk factors for AKI vary depending on the patient type. Few studies have focused on the risk factors for developing AKI in the general ICU population. one study of 40 ICUs in 16 countries evaluated risk factors using the Sequential organ Failure Assessment score (n=1411) 43 . The most important risk factors for AKI were age >65 years, infection, acute circulatory or respiratory failure, past history of chronic heart failure, lymphoma/leukaemia or cirrhosis (odds ratio >1.4, P <0.05) 43 . A recent study of risk factors for AKI after major non-cardiac surgery in patients with previously normal renal function (n=1166) found that age, American Society of Anesthesiologists physical status, emergency surgery, high-risk surgery, ischaemic heart disease, congestive heart disease and Revised Cardiac Risk Index score were independent preoperative determinants for AKI 44 .
In the many studies of risk factors for AKI after cardiac surgery, a wide variety of causes have been implicated. Factors most consistently associated with development of postoperative AKI are duration of cardiopulmonary bypass and advanced age [45] [46] [47] , followed by preoperative impaired renal function, diabetes, the need for perioperative intra-aortic balloon pump or evidence of ventricular dysfunction. Interestingly, one study that focused on potentially modifiable risk factors for AKI and compared results of three definitions of AKI (>25, >50 and >75% decrease in estimated GFR, n=3460) 47 found that preoperative anaemia, perioperative red blood cell transfusions and need for surgical re-exploration were also strongly associated with AKI using all three definitions.
The use and age of blood products in critically ill patients and their potential association with poor outcomes, including the development of AKI, is an area of increasing investigation and of relevance to anaesthetists and intensive care clinicians. A landmark study by Koch and colleagues 48 (n=2872) comparing outcomes in patients receiving 'newer' versus 'older' stored red cells (blood stored for ≤14 days or for >14 days respectively) found that patients given 'older' blood were more likely to have kidney injury (2.7 vs 1.6%, P=0.003). An Australian study called Standard issue transfusion versus fresher red blood cell use in intensive care-a randomised controlled trial (NCT01638416, n=5000) will investigate the effect of using the freshest available red blood cells compared to standard practice (oldest available red blood cell unit) on 90-day mortality and need for renal replacement therapy (RRT) in critically ill patients.
Another area of concern is the potential association of hydroxyethyl starch use and the development of AKI. In a recent Cochrane review 49 , patients treated with hydroxyethyl starch compared with other fluid therapies had a relative risk for kidney failure of 1.5 (95% confidence interval 1.2 to 1.87, n=1199) and 1.38 for requiring RRT (0.89 to 2.16, n=1236). Interestingly, the risk of developing kidney failure in studies including septic patients was higher than in surgical and trauma patients.
In a recent trial of hydroxyethyl starch versus a balanced crystalloid solution in patients with severe sepsis (n=798), those receiving starch had an increased risk of death at day 90 and were more likely to require renal-replacement therapy 50 . Starch based solutions may also have an adverse effect on coagulation and inflammatory markers 51, 52 . Histological renal tubular damage is observed with experimental hydroxyethyl starch administration 53 . Moreover, hypertonic hydroxyethyl starch may induce a pathological state known as 'osmotic nephrosis' 54 , whereby hydroxyethyl starch molecules enter renal proximal tubular cells by pinocytosis. The resulting vacuoles fuse with each other and with lysosomes to form larger vacuoles containing hydroxyethyl starch molecules and hydrolytic enzymes. This may cause swelling of tubular cells and vacuolar retention if the agent is only slowly digestible by the lysosomal enzymes. This lysosomal alteration is an early sign of cell damage and is reversible but may be a first step in the development of irreversible tubular cell lesions.
The results of a multicentre Australian and New Zealand randomised controlled trial (n=7000), which completed recruitment early in 2012 (NCT00935168), further support the lack of benefit of starch solutions for critically ill patients and further highlight their negative impact on renal function.
Finally, other general interventions may be of relevance to the kidney. For example, the protective effect of erythropoietin and hypothermia for the kidneys is also under investigation in sub-studies of two Australian-based multicentre clinical trials (ACTRN12609000827235 and ACTRN12609000764235, respectively).
PATHOGENESIS
The development of AKI in critically ill and postoperative patients is complex and multifactorial, and in developed countries is largely the result of [56] [57] [58] [59] . AKI=acute kidney injury, ATN=acute tubular necrosis, h=increased, i=decreased, GFR=glomerular filtration rate, g=lead to. prerenal causes 2, 22 . Consequently, we will focus on this area, rather than AKI resulting from less common inflammatory or obstructive disease or vascular events.
AKI: animal models
our understanding of the pathogenesis of prerenal AKI comes largely from animal models because the invasive investigations necessary to our understanding of the pathogenesis of AKI cannot be performed in man. These models predominantly involve the occlusion of the arterial blood supply to the kidney to induce ischaemia, although models of ureteric obstruction and transplant are also in use 55 . AKI and acute tubular necrosis are induced by the occlusion model of ischaemia ( Figure 5 summarises the reported biological effects of subsequent reperfusion injury in these models). Studies using several laboratory technologies have shown that a multitude of pathways and mechanisms are most likely involved ( Figure 5 ) [56] [57] [58] [59] .
Unfortunately such models lack clinical relevance for the conditions that most commonly trigger AKIsepsis, major surgery (most importantly cardiac surgery) and acute heart failure-none of which involve occlusion of the renal artery 60, 61 . More relevant models are required.
Models of septic AKI that adequately reflect human AKI are challenging to develop. Endotoxin bolus induces hypodynamic shock with low cardiac output in small animals 60, 62 , which confounds the model by combining septic and cardiogenic shock, a state very different from human sepsis where a hyperdynamic state is most common. Interestingly, when hyperdynamic sepsis is induced in large animals (mostly sheep), AKI develops as expected, but marked global renal vasodilation occurs, renal blood flow (RBF) increases above normal levels and there is no histopathological injury 62,63 despite severely decreased urine output and increased serum creatinine. Thus, experimental septic AKI can occur while RBF is abnormally high. This observation challenges the notion that all prerenal AKI must be due to hypoperfusion. It also raises questions about how GFR can be lost in the setting of markedly increased RBF. Possible explanations include efferent arteriolar vasodilatation with decreased intraglomerular filtration pressure and/or intrarenal blood flow redistribution (shunting).
Irrespective of the complexity of intrarenal events, different septic models lead to variable systemic and renal haemodynamic states, and it is not possible to know which models are most relevant to human sepsis. It seems clear, however, that current animal models of ischaemic AKI have limited explanatory value in the setting of sepsis, which is the most common trigger of AKI in patients in developed countries.
RBF could also increase in humans with septic AKI and there is currently no way to disprove this possibility 64 . Moreover, recent studies suggest that variations to the renal microcirculation may have more impact on renal function than changes in global RBF 65, 66 . Even if success in increasing urine output was achieved by a better understanding of mechanisms responsible for its decrease, restoring urine output when the kidneys are under physiological stress may be harmful due to increased oxygen demand 67 . Furthermore, we cannot be certain that acute tubular necrosis occurs in human sepsis if there is evidence that septic animals and humans lose their renal function without any histopathological changes 68, 69 . These observations highlight the many uncertainties that surround septic AKI and its pathogenesis.
Anaesthesia-related models of AKI
Anaesthesia-related rodent models of ischaemiareperfusion AKI often use excision of the right kidney followed by occlusion of the left renal artery using clamps 70 . More recently, occlusion via a hangingweight system has been introduced 71 , which reportedly creates highly reproducible injury, thus minimising the variability associated with clamping. Bilateral nephrectomy 70 and transplant 72 models have also been used. While factors contributing to the development of surgical AKI may include a reduction in RBF, renal artery occlusion and bilateral nephrectomy do not adequately represent the conditions they aim to replicate. Caecal ligation and puncture-induced sepsis models have been used to evaluate the effect of anaesthesia on sepsis-induced AKI. Caecal ligation and puncture mice become hypotensive without a hyperdynamic phase 73 , although vigorous fluid resuscitation provides an early hyperdynamic phase 74 . Caecal ligation and puncture-induced sepsis mimics more clinical features and drug responses of human sepsis than endotoxin bolus models but does not consistently lead to the development of AKI 60 .
Models of postoperative AKI
These models generally seek to evaluate the effect of certain human surgical procedures on the development of AKI and are fairly representative replications in rodents of such surgery, but have the inherent limitations of many non-human models. Such models include orthotopic liver transplant 75 , kidney transplant and juxtarenal abdominal aortic aneurysm repair 76 . Conventional surgical ischaemic AKI models involve a laparotomy with renal pedicle occlusion 77 or left renal artery clamp occlusion 78 . once again, such injury is not a realistic replication of what occurs in human abdominal surgery outside of specific vascular interventions.
Models of cardiac surgery and AKI
Cardiopulmonary bypass models attempt to replicate in animals the effects of a bypass procedure 79, 80 , with the limitations of non-human models. Most conventional ischaemia-reperfusion mouse models use renal pedicle clamping (both artery and vein). However, most patients who develop cardiac surgeryassociated AKI have only renal artery hypoperfusion 77 . A recent study found that renal artery occlusion and pedicle occlusion produce less tubular injury than renal vein occlusion, due to less kidney congestion 77 . Understanding such differences is important for the design of future experimental studies in mice and highlights the poorly appreciated role of congestion compared with ischaemia.
Human research
Although more human investigation would seem logical considering the problems with animal models of AKI, the fact that there is no known effective intervention for histologically confirmed AKI makes this difficult and renal biopsies cannot be justified. In addition, mechanistic investigations in humans are extraordinarily difficult or even sometimes impossible. Thus, investigations are limited to post-mortem studies with their inherent problems: selection bias, pre-mortal ischaemia and hypoxia. Similarly, there is no accurate, continuous, non-invasive technique to measure RBF in humans 64 . New non-invasive methods to measure RBF such as magnetic resonance techniques and contrast enhanced ultrasonography are under development 81, 82 , but they are difficult to apply outside the research environment. Data for RBF from invasive techniques 83 should be viewed with caution as they are taken in patients with AKI who may have organ oedema, tubular damage, backleak and increased tubular luminal pressure, which could produce changes in RBF. Reduced RBF may therefore be the result of AKI and not the causative mechanism, or it could be both. Human models of AKI in cardiac surgery have, unfortunately, not provided specific insights into its pathophysiology. Renal transplant models, on the other hand 84 , allow tissue examination but are affected by nephrotoxic drugs, and results from such models where kidneys are kept under artificial conditions cannot be extrapolated to common triggers such as sepsis or major surgery.
Neurohormonal response
In the presence of AKI, kidney-specific neurohormonal responses seem to be activated 85 . Experimental and human studies of AKI indicate that RAAS, the tubuloglomerular feedback system and the renal sympathetic system are activated 85, 86 . In the setting of sepsis, it is thought that infection results in nitric oxide synthase induction with subsequent vasodilation. This leads to arterial volume depletion and baroreceptor activation, triggering sympathetic system activation, which induces heightened RAAS activity and renal vasoconstriction. Vasopressin is also released enhancing water retention 85 . However, the relative importance of each mechanism and the timing of onset and duration of their occurrence remain uncertain. This hinders the development of new interventions.
Whether neurohormonal changes cause intrarenal shunting, and whether this shunting contributes to reduced GFR and ischaemia of the renal medulla, is unknown. Shunting may be linked to microcirculatory changes, and assessment of the microcirculation should be performed with any global RBF measurements performed in animals (limited to animals as techniques are invasive) to enhance our understanding of AKI.
Renal biomarker studies in the critically ill suggest the involvement of different underlying pathophysiological processes in septic and non-septic AKI 87 .
Effects of anaesthesia and surgery on renal function
Volatile anaesthetics may reduce GFR as a result of a reduction in renal perfusion pressure either by decreasing systemic vascular resistance (e.g. isoflurane or sevoflurane) or cardiac output (e.g. halothane). This reduction in GFR is exacerbated by hypovolaemia and catecholamine, and antidiuretic hormone release in response to painful stimuli during surgery 88 . Recent studies have found that volatile anaesthetics that reduce GFR, such as isoflurane, also ameliorate renal injury with a subsequent reduction in hepatic and intestinal multiorgan failure after renal ischaemia-reperfusion injury 70, 89 . This may be related to a reduction in necrosis, inflammation and the severity of kidney injury when isoflurane activates certain cytoprotective signalling pathways in human proximal tubule cells 89 . Sevoflurane, previously thought to be a potential cause of kidney injury due to fluoride toxicity 90 , is now considered safe, even at low flows 91 . Similarly, propofol may inhibit pro-inflammatory cytokines in septic animal models 92, 93 . While the mechanisms are unclear, recent animal studies indicate that propofol could decrease inflammatory cytokines and oxidative stress by inhibiting free radical generation, increasing bone morphogenetic protein-7 expression during septic AKI and regulating other inflammatory factors 92 . The use of methoxyflurane as a general anaesthetic was abandoned in the 1970s due to its dose-dependent nephrotoxicity. It is now used in Australia as an emergency short-term analgesic, largely in the prehospital setting via the self-administered Penthrox ® inhaler (Medical Developments International Limited, Springwood, Victoria) 94 . Used in this way at a low and limited dose with a contraindication for its use in people with any degree of kidney injury, there is no indication of a harmful effect on the kidneys 95 .
Perioperative procedures can contribute to the development of AKI. Positive pressure ventilation during general anaesthesia can decrease cardiac output leading to catecholamine, renin and angiotensin II release with sympathoadrenal activation and reduction in renal blood flow, increasing the risk for AKI. Abdominal insufflation during laparoscopic surgery, with the associated increased intraabdominal pressure, has a similar effect on RBF and GFR 96 . During liver transplantation, aortic crossclamping or inferior vena cava occlusion can cause AKI, thus increasing mortality and morbidity 97 .
In the setting of pre-existing kidney injury, the dependence of many anaesthetic drugs on renal excretion should always be considered. In these patients, increased sensitivity to barbiturates and benzodiazapines occurs due to decreased proteinbinding, resulting in an increase in active drug-causing pharmacological effects. Judicious use of opioids with a preference for fentanyl and hydromorphone over morphine and pethidine is advised 91 . Fentanyl has a rapid onset, a shorter half-life and greater potency than morphine. It is highly lipid-soluble facilitating its passage across the blood-brain barrier 98 . The severe side-effects of pethidine (serotonin syndrome, seizures, delirium, dysphoria and tremor) are due to the action of its metabolite norpethidine which has convulsant and hallucinogenic effects 99 be avoided if the patient's potassium level is high or unknown; it consists of two acetylcholine molecules and if cellular acetylcholine receptors remain open, potassium can move out to the extracellular fluid causing hyperkalaemia. Non-depolarising muscle relaxants cisatracurium and atracurium do not rely on renal excretion for their elimination and are preferred to other neuromuscular blockers whose effects may be prolonged 100 . Antimicrobials should be dosed according to renal function, and non-steroidal anti-inflammatory drugs may exacerbate renal injury and should be avoided. Patients with kidney disease or a high-risk for postoperative AKI may benefit from a sympathetic block for T4-T10 to attenuate catecholamineinduced renal vasoconstriction and suppress cortisol and adrenaline release 101 . Similarly, the use of postoperative epidural anaesthesia, where appropriate, may reduce the incidence of AKI, but this has not yet been definitely established 102 . For elective surgical patients with chronic kidney disease, dialysis is recommended the day before surgery, and patients with pre-existing AKI undergoing major surgery require invasive monitoring and frequent postoperative biochemical monitoring.
AKI after cardiac surgery
Several pathophysiological mechanisms come into play with cardiac surgery and collectively contribute to the development of AKI at different stages ( Figure  6 ) 103 . Furthermore, worsening of preoperative renal dysfunction is associated with longer length-of-stay, increasing operative mortality, prolonged mechanical ventilation and increasing need for RRT 4, 104 .
As described earlier, preoperative use of certain antibiotics, non-steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors or contrast agents can cause or predispose patients to AKI. However, apart from contrast-induced AKI, their impact is minimal.
Pro-thrombotic drugs such as aprotinin, aminocaproic acid and tranexamic acid are given after cardiopulmonary bypass and may cause renal injury. In adult cardiac surgery, aprotinin use is associated with an increased risk for AKI 105, 106 , and its supply worldwide was suspended after the Blood conservation using Antifibrinolytics in a Randomised Trial 107 found the risk of death was higher with aprotinin use compared to the use of lysine analogues. However, recent paediatric cardiac surgery trials revealed mixed results 108 , and a recent US 'post-aprotinin era' study 109 showed that the relative risk of early postoperative kidney injury and mortality have not improved since the suspension of aprotinin, while intraoperative blood product use has increased. Recent news that the suspension of aprotinin in Europe may be lifted 110 indicates that controversy remains.
Metabolic factors
Diabetes is an independent predictor of postoperative AKI in patients with normal preoperative kidney function 111 and hyperglycaemia is associated with a higher incidence of postoperative AKI. However, intensive intraoperative insulin therapy has not been shown to reduce the incidence of AKI compared to conventional glucose control 112 . A factorial design trial (NCT00995501) to investigate the effects of dexamethasone, tight glucose control and depth-of-anaesthesia on peri-operative inflammation and morbidity in major non-cardiac surgery may help to clarify this. obesity (body mass index 30 to 40) and, conversely, a body mass index <20 and albumin <25 g/l (measures of malnutrition) are associated with a higher incidence of postoperative AKI 113, 114 .
Neurohormonal activation
Preoperatively, this commonly occurs in patients with chronic heart failure. Low cardiac output syndromes lead to elevated sympathetic nervous system activity, activation of the renin-angiotensinaldosterone system and higher levels of circulating vasopressin 103 . This then leads to general vasoconstriction, reduced renal filtration and sodium, and water retention, which increases the renal risk in heart surgery. Plasma levels of adrenaline, noradrenaline, vasopressin, dopamine, a trial natriuretic factor and prolactin rise during cardiopulmonary bypass, as does renin activity. Their levels fall at different times with a net effect of reduced renal blood flow and GFR, thus increasing the risk for kidney injury 103 . After cardiac surgery, patients are overloaded with fluid. Natriuretic peptides may be of benefit in 'at risk' patients with syndromes of excessive neurohormonal activation by helping to increase GFR and promote diuresis and natriuresis 115, 116 , however this requires further investigation.
Inflammation
There is a strong association between postoperative complications and preoperative C-reactive protein (area under the curve=0.86) and IL-6 (area under the curve=0.79) 117 . The level of baseline systemic inflammation appears to be related to levels immediately after cardiac surgery 118 . After cardiopulmonary bypass in children, surges in novel markers of injury were followed by inflammatory markers (C-reactive protein and interleukins), peaking at 24 hours after bypass 119 . However, a recent Cochrane Review showed no benefit of corticosteroid use in cardiopulmonary bypass 120 
. Inflammation and levels
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Oxidative stress
This is thought to be an important mechanism of renal injury. As free radicals are difficult to measure, levels of antioxidant defences or the products of oxidative damage are assayed as indirect measures of oxidative stress. Contrast-induced nephropathy may be mediated by oxidative stress 123 , and gentamicin, iron and radiocontrast may promote the generation of oxygen metabolites 124 . Animal studies have shown that antioxidant therapy with NAC prevented lipid peroxidation and caused increased antioxidant activity in renal tissue after cardiopulmonary bypass 80 . However, a recent study of cardiac bypass surgery patients found that markers of oxidative stress did not correlate with the progression of AKI, but the levels of plasma neutrophil gelatinase-associated lipocalin (NGAL) in the first few hours after bypass were predictive of AKI 125 . This suggests a greater involvement of inflammatory processes in the development of AKI at this stage, which is consistent with findings of no benefit of NAC on renal function in clinical trials 126, 127 .
In summary, the pathogenesis of post cardiopulmonary bypass AKI is extraordinarily complex and no intervention has been consistently shown to attenuate this injury.
DIAGNOSIS
AKI generally occurs in the setting of other acute illness and carries no reliable clinical signs or symptoms. oliguria may develop early but is nonspecific. Other signs and symptoms do not present until advanced loss of function has occurred. In most cases, AKI is diagnosed in a high-risk setting, such as sepsis, haemorrhagic shock, cardiac surgery, trauma, major emergency surgery, advanced liver disease or heart failure. Its diagnosis is based on the clinical context, changes in urine output and the measurement of waste products of nitrogen metabolism (creatinine or urea) and renally excreted electrolytes (especially potassium and phosphate). To rule out the possibility of chronic kidney disease in patients with an elevated serum creatinine, the clinical context must be taken into account. Factors suggestive of chronic kidney disease include prior elevated serum creatinine, known risk factors for chronic kidney disease, a very high serum creatinine and/or phosphate, anaemia, a slow clinical course or small kidneys on ultrasound.
Serum creatinine is the most commonly used marker of renal function. However, its use as a marker of AKI has several limitations. First, its release varies with age, gender, muscle mass, diet, exercise and drugs. Second, its secretion in the tubules accounts for 10-40% of creatinine clearance and can mask a decrease in GFR. Finally, a decrease of at least 50% in GFR is needed before serum creatinine becomes abnormal, and more than 24 hours may pass before a sufficient increase in blood concentration is detectable. of relevance to anaesthetists and often not fully appreciated, fluid resuscitation and a positive fluid balance may artificially lower serum creatinine, confounding diagnosis. In a post hoc analysis of the Fluid and Catheter Therapy Trial cohort (n=1000), Liu and colleagues found that the incidence of AKI (creatinine-classified) before adjustment for fluid balance was greater in patients managed with a conservative fluid protocol (57 vs 51%, P=0.04). However, after adjustment for fluid balance, the incidence of AKI was greater in patients managed with the liberal fluid protocol (66 vs 58%) 128 . Moreover, those with AKI identified after adjustment for a positive fluid balance had a higher mortality rate than patients who did not meet AKI criteria both before and after adjustment for fluid balance (31 vs 12%, P <0.001). The impact of fluid balance on classification of AKI should therefore be considered in future studies of AKI.
The RIFLE and RIFLE/AKIN classification systems for AKI, which use serum creatinine, have been discussed earlier. If estimated GFR is used to classify renal function, the Modification of Diet in Renal Disease abbreviated equation, which incorporates creatinine, age and gender, is widely used and validated for its calculation 129 . Estimated GFR has been successfully used to classify acute kidney injury in critically ill patients using the RIFLE GFR criteria 4, 18, 104 .
Like creatinine, plasma urea also has limited reliability in estimating GFR. Its production and renal clearance are not constant and levels can be altered by changes in circulatory volume, protein intake and gastrointestinal bleeding. Urea also requires time to accumulate and delays diagnosis, making it a poor measure of GFR.
Urine output is monitored in surgery and ICUs by indwelling catheters. Trends in urine output help gauge kidney function and may better reflect a change in renal haemodynamics than solute clearance 1 . Urine output lacks specificity and sensitivity and is affected by several drugs (i.e. diuretics and vasopressors) reducing its utility as a marker of renal function.
other methods for diagnosing AKI include inulin clearance which has been regarded as the most accurate method for determining GFR for research in the past. However, an intravenous infusion is required, and inulin measurement is expensive and labour-intensive, making it an impractical option. Radionuclide-based tests have performed well, although such methods are too complex for clinical use.
Novel biomarkers for AKI
The lack of adequate methods for the diagnosis of AKI has opened up a new field of research in AKI [130] [131] [132] [133] [134] . Innovative technologies such as proteomics have facilitated the detection of several new biomarkers of AKI (Table 1) 135 . Amongst the most promising of these are NGAL and cystatin C, which have been evaluated, predominantly after cardiac surgery, in general ICU patients and on emergency department presentation 133, 136 . They assess complementary aspects of renal injury (NGAL: tubular stress; cystatin C: GFR) 137 . The utility of different biomarkers for each RIFLE classification stage is summarised in Table 1 .
Certain key points can be made. First, the concentration of these biomarkers seems to change earlier than creatinine in patients who develop AKI. If AKI was detected early, clinicians might be able to treat it sooner and have a better chance of preventing or reducing injury. Second, the biomarkers respond to treatment or recovery making them potentially useful to evaluate the effect of interventions such as perioperative haemodynamic optimisation of highrisk surgical patients on renal function and as safety markers to monitor toxicity 138, 139 . Third, they appear to be more sensitive than creatinine and respond to 'subclinical' degrees of kidney injury that pass undetected by creatinine, yet are associated with worse outcomes. Indeed, recent studies suggest that NGAL may detect subclinical states of AKI that are associated with increased risk of RRT, hospital mortality or length-of-stay 140, 141 . Furthermore, biomarker combinations may offer improved prediction of AKI beyond clinical models, and provide severity and prognostic information at an early stage in the development of injury. This would allow the application of potential therapies at appropriate time points. Finally, biomarkers may help elucidate the potential mechanisms of injury of AKI; this is manifested in a recent investigation surrounding the pathophysiological processes of septic AKI 87 .
The arrival of new biomarkers of AKI has allowed a re-evaluation of mechanisms, timing and pathogenesis in this area, and new biomarkers continue to emerge 130, 132, 133, 142 . This field could lead to therapeutic benefit and eventual modification of the definition of AKI. However, no biomarker-guided interventional study has yet been conducted and their ability to guide therapy remains unknown.
PREVENTIoN AND TREATMENT
Investigation of pharmacotherapies to prevent or ameliorate AKI has been disappointing. Loop diuretics do not reduce the incidence of AKI 143 . The proposed nephroprotective effect of 'low-dose' dopamine was refuted in postoperative and general critically ill patients 144 . Fenoldopam, a vasodilator, may reduce the need for RRT after cardiac surgery 42 but has shown inconsistent results in different settings. Natriuretic peptides have only shown unconfirmed promise in major surgery 42 . Calcium channel antagonists show no benefit on postoperative renal function after cardiac surgery and unconvincing evidence for a benefit in non-cardiac surgery 42 . Despite promising results in experimental studies, N-acetylcysteine after radiocontrast and before cardiac surgery to prevent AKI has shown unconvincing results 145, 146 , and it is doubtful whether a perioperative intravenous sodium bicarbonate infusion for cardiac surgical patients is nephroprotective 147, 148 , despite promising results from an early pilot study 149 .
The lack of success in finding a consistently effective treatment for AKI has several explanations. First, multiple causes and disease processes contribute to the development of AKI and this heterogeneity of causes and likely pathogenesis means finding a common treatment will be unlikely. Second, limited knowledge of the disease processes involved in the development of AKI makes planning of investigations into the prevention or treatment of AKI difficult. Third, if interventions are only guided by conventional markers (creatinine, urea, urine output) which only become deranged very late in the course of injury, they may be initiated too late for treatment to be effective. This problem has profoundly hindered therapeutic progress in this area. Timely fluid resuscitation (avoiding overload) and appropriate titration of inotropes/vasopressors to maintain adequate perfusion pressure and cardiac output remain the only widely accepted therapy to prevent or treat AKI. Indeed, protocolised perioperative optimisation of haemodynamic and oxygenation parameters using oxygen, fluids and inotropes/vasopressors in high-risk surgical patients with septic shock may reduce mortality and the risk of AKI 150 . However, the optimal perioperative fluid regimen is uncertain and increasing evidence suggests that better outcomes are associated with more restrictive fluid replacement practice 151, 152 . A recent systematic review of randomised controlled trials of goal-directed therapy-based, haemodynamicallytargeted fluid resuscitation found that this practice was associated with decreased incidence of AKI after major surgery 153 . However, the benefit could not be attributed to the provision of greater volumes of fluid to hypovolaemic patients, but rather, the use of inotropes with goal-directed therapy and an equivalent amount of fluid resuscitation between groups seemed to be associated with a lower incidence of AKI. Perhaps providing fluid earlier and faster with inotropic support minimises the harmful effects of fluid overload. In Australia this has led to the development and design of the first large multicentre, randomised controlled trial to determine whether a restrictive versus liberal (current practice) perioperative fluid regimen decreases mortality (NCT01424150). This trial will be the first phase III trial of fluid therapy in the perioperative period ever conducted.
Further measures to prevent/treat AKI include avoidance of nephrotoxic drugs, maintenance of adequate oxygenation and haemoglobin concentration, monitoring of volume status with preference for euvolaemia and maintaining plasma glucose between 8-10 mmol/l in critically ill patients receiving insulin therapy 7 . The administration of fluids containing starch should be avoided due to a demonstrated lack of benefit for critically ill patients and for their association with increased need for RRT 49, 50 . Whether the pleiotropic effects of erythropoietin are protective of the kidneys requires more investigation in humans 154, 155 .
Patients who develop progressive azotaemia, hyperkalaemia, metabolic acidosis or fluid overload will generally require RRT as supportive therapy.
Renal Replacement Treatment
There is insufficient evidence to indicate the best time to commence RRT, although observational studies 156 suggest benefit from early initiation 157 . The recognition of the contribution of even low levels of fluid overload (10-20%) to increased risk of adverse clinical outcomes in AKI patients 158 , lends more weight to the recommendation of early RRT for severely oliguric patients.
Studies do not show a survival advantage between available RRTs commonly used in developed countries such as intermittent haemodialysis, slow low-efficiency dialysis or continuous renal replacement therapy (CRRT) 159 . of note, in RRT patients, RIFLE seems less effective in predicting risk of death, which may be due to the inability to discriminate between the R, I and F classes in such a sick population 2 . Nonetheless, in the RENAL trial (almost exclusively CRRT), renal recovery was far greater than in the ATN trial (considerable use of intermittent haemodialysis), supporting the potential benefit of CRRT for renal recovery 160 . In addition, there is a consensus that in patients who are vasopressor dependent, CRRT should be the treatment of choice 159, 160 . In Australia and New Zealand, CRRT is the dominant approach to RRT in the ICU.
Regarding the intensity of RRT, both the ATN and RENAL trials showed no benefit from the use of a higher intensity of RRT 161, 162 . A dose of 25-30 ml/kg/ hour of effluent generation is recommended 163 . How to decide when to stop CRRT is uncertain, however, a spontaneous urine output of over 500 ml/day may help in determining when to consider a trial off CRRT 164 .
THE FUTURE
The mortality associated with severe AKI, particularly in critically ill patients, remains very high. The ATN and RENAL trials revealed mortality rates of 53 and 44.7%, respectively. Moreover, postoperative AKI is one of the most serious complications in surgical patients and accounts for 18-47% of all cases of hospital-acquired AKI 165 . of equal concern, recent studies indicate a link between AKI and subsequent progression to chronic kidney disease, end-stage kidney disease and mortality 166, 167 . This implies that a short episode of AKI may contribute to kidney/ patient morbidity and mortality in the long-term, which would increase the human and financial costs of AKI far beyond current projections. Whether this increased risk of chronic kidney disease is a direct effect of AKI or whether AKI is simply yet another marker of patients predisposed to chronic kidney disease, or both, warrants further investigation.
There is growing interest in the potential renal protection that remote ischaemic preconditioning could provide for patients undergoing major surgery 168 and larger trials are currently underway (NCT01067703, n=2070). The apparent negative effect of saline and other chloride-rich fluids on renal function is also of increasing interest 169 . A recent observational study in abdominal surgery patients found that the use of 0.9% saline compared to a balanced fluid resulted in an increased risk for dialysis requirement 170 .
The need for earlier detection of AKI and investigation into effective treatments is evident, with the evaluation of novel early biomarkers for AKI and development of targeted therapies becoming a priority. Certain biomarkers appear to rise and respond to specific subgroups of AKI in different time frames and at different levels. We may, therefore, see the development of biomarker 'panel' tests, which might detect the presence of AKI early and perhaps give an indication of the type/cause of AKI. This, in turn, would facilitate the investigation and development of targeted treatments for AKI with biological agents (e.g. erythropoietin) or broad biological modifiers (e.g. cooling).
Erythropoietin and therapeutic hypothermia are two treatments that have shown potential as kidney protective therapies. They are being investigated in renal sub-studies of two large multicentre randomised controlled trials: Erythropoietin in traumatic brain injury (ACTRN12609000827235) and Prophylactic hypothermia to lessen traumatic brain injury (ACTRN12609000764235). These sub-studies will include the use of multiple biomarkers to evaluate the effects of the interventions and the diagnostic, prognostic and treatment monitoring value of the biomarkers when used in combination.
CoNCLUSIoN
AKI is a major contributing factor to adverse outcomes after major surgery and in critically ill patients. Its consensus classification has facilitated AKI research, and the intense investigation of early biomarkers of AKI may lead to expanded definitions that incorporate the new concept of 'subclinical' AKI and open the door to earlier and better targeted interventions. As the pathophysiology of AKI becomes better understood, some previously held beliefs are being questioned and our ability to develop interventions and implement them at the optimum time will improve. The results of the Crystalloid versus hydroxyethyl starch trials (NCT00935168), the future Restrictive versus liberal fluid therapy in major abdominal surgery: RELIEF study (NCT01424150) and several new lines of AKI research will provide greater insight into the prevention and treatment of AKI and assist anaesthetists and intensive care clinicians in providing better care to their increasingly high-risk patients.
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